<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2017-10-36-40</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-1865</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕРВНО-ПСИХИЧЕСКИЕ РАССТРОЙСТВА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROPSYCHIATRIC DISORDERS</subject></subj-group></article-categories><title-group><article-title>ТРЕВОЖНЫЕ РАССТРОЙСТВА В ОБЩЕКЛИНИЧЕСКОЙ ПРАКТИКЕ</article-title><trans-title-group xml:lang="en"><trans-title>ANXIETY DISORDERS IN CLINICAL PRACTICE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левин</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Levin</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медиинских наук,  профессор.</p><p>Москва</p></bio><bio xml:lang="en"><p>MD, Prof.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Российская медицинская академия  непрерывного  профессионального  образования Минздрава России<country>Россия</country></aff><aff xml:lang="en">Russian Medical Academy of Continuous Vocational Education of the Ministry of Health of Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>24</day><month>05</month><year>2017</year></pub-date><volume>0</volume><issue>10</issue><fpage>36</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Левин О.С., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Левин О.С.</copyright-holder><copyright-holder xml:lang="en">Levin O.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/1865">https://www.med-sovet.pro/jour/article/view/1865</self-uri><abstract><p>Тревожные расстройства – группа феноменологически  близких, но этиопатогенетически разнородных психопатологических состояний. Cвоевременное распознавание и коррекция тревожных расстройств обеспечивают долгосрочный эффект и могут рассматриваться  как форма первичной профилактики сердечно-сосудистых и других соматических и неврологических заболеваний. При тревожных расстройствах у больных с соматическими заболеваниями в основе лечения должна лежать адекватная терапия первичной болезни. В легких и умеренных случаях тревожного расстройства, особенно при выраженных соматоформных проявлениях и нежелательности седативного эффекта, наиболее предпочтительно применение тофизопама.</p></abstract><trans-abstract xml:lang="en"><p>Anxiety disorders are a group of phenomenologic  close  but etiopathogenetically  heterogeneous  psychopathologic states. Modern recognition and correction of anxiety disorders provide a long-term effect and can be seen as a form of primary prevention of cardiovascular and other somatic and neurological diseases. In case of anxiety disorders patients with somatic illnesses should be treated with adequate primary illness therapy. In light and moderate cases of anxiety disorders, especially in the somatoform manifestations and the undesirability of sedation the use of Tofisopam is preferable.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тревожные расстройства</kwd><kwd>бензодиазепиновые анксиолитики</kwd><kwd>тофизопам</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Anxiety disorders</kwd><kwd>benzodiazepine anxyolytics</kwd><kwd>Tofizopam</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Артеменко А.Р., Окнин В. Ю. Грандаксин в лечении психовегетативных расстройств. Лечение нервных болезней, 2001, 2(1): 24-27.</mixed-citation><mixed-citation xml:lang="en">Артеменко А.Р., Окнин В. Ю. Грандаксин в лечении психовегетативных расстройств. Лечение нервных болезней, 2001, 2(1): 24-27.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Вейн А.М., Дюкова Г.М.. Воробьева О.В., Данилов А.Б. Панические атаки (неврологические и психофизиологические аспекты). 1997. СПб. С. 304.</mixed-citation><mixed-citation xml:lang="en">Вейн А.М., Дюкова Г.М.. Воробьева О.В., Данилов А.Б. Панические атаки (неврологические и психофизиологические аспекты). 1997. СПб. С. 304.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Вейн А.М. Рябус М.В. Грандаксин в лечении эпизодической головной боли напряжения. Лечение нервных болезней, 2000, 1(1): 14-16.</mixed-citation><mixed-citation xml:lang="en">Вейн А.М. Рябус М.В. Грандаксин в лечении эпизодической головной боли напряжения. Лечение нервных болезней, 2000, 1(1): 14-16.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мосолов С.Н. Основы психофармакологии. М. Восток. 1996. 288 с.</mixed-citation><mixed-citation xml:lang="en">Мосолов С.Н. Основы психофармакологии. М. Восток. 1996. 288 с.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Соловьева А.Д., Буячинская А.И. Грандаксин в лечении предменструального синдрома. Лечение нервных болезней, 2001, 2, 3(5): 29-31.</mixed-citation><mixed-citation xml:lang="en">Соловьева А.Д., Буячинская А.И. Грандаксин в лечении предменструального синдрома. Лечение нервных болезней, 2001, 2, 3(5): 29-31.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">British Medical Association, Royal Pharmaceutical Society of Great Britain.UK, BMJ Group and RPS Publishing, 2010: 212.</mixed-citation><mixed-citation xml:lang="en">British Medical Association, Royal Pharmaceutical Society of Great Britain.UK, BMJ Group and RPS Publishing, 2010: 212.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">DSM-V. APA, 2013.</mixed-citation><mixed-citation xml:lang="en">DSM-V. APA, 2013.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chopin P, Stenger A, Couzinier JP, Briley M. Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. J. Pharm. Pharmacol, 1985, 37(12): 917-9.</mixed-citation><mixed-citation xml:lang="en">Chopin P, Stenger A, Couzinier JP, Briley M. Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. J. Pharm. Pharmacol, 1985, 37(12): 917-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Holt RIG, Maj M (eds). Comorbidity of Mental and Physical Disorders. Key Issues Ment Health. Basel, Karger, 2015, 179: 81087.</mixed-citation><mixed-citation xml:lang="en">Holt RIG, Maj M (eds). Comorbidity of Mental and Physical Disorders. Key Issues Ment Health. Basel, Karger, 2015, 179: 81087.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Horvth EJ, Horvth K, Hmori T, Fekete MI, Silyom S, Palkovits M. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol, 2000, 60(4): 309-42.</mixed-citation><mixed-citation xml:lang="en">Horvth EJ, Horvth K, Hmori T, Fekete MI, Silyom S, Palkovits M. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol, 2000, 60(4): 309-42.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kanto J, Kangas L, Leppnen Ф, Mansikka М, Sibakov ML Toftzopam: a benzodiazepine derivative without sedative effect. Int J Clin Pharmacol Ther Toxicol, 1982, 20(7): 309-12.</mixed-citation><mixed-citation xml:lang="en">Kanto J, Kangas L, Leppnen Ф, Mansikka М, Sibakov ML Toftzopam: a benzodiazepine derivative without sedative effect. Int J Clin Pharmacol Ther Toxicol, 1982, 20(7): 309-12.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kato R, Ooi K, Ueno K. A case in which tofisopam was effective for treatment of paroxysmal supraventricular tachycardia. Yakugaku Zasshi, 2003, 123(5): 365-8.</mixed-citation><mixed-citation xml:lang="en">Kato R, Ooi K, Ueno K. A case in which tofisopam was effective for treatment of paroxysmal supraventricular tachycardia. Yakugaku Zasshi, 2003, 123(5): 365-8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Loane C, Politis M. Buspirone: what is it all about? Brain Res, 2012, 1461: 111-118.</mixed-citation><mixed-citation xml:lang="en">Loane C, Politis M. Buspirone: what is it all about? Brain Res, 2012, 1461: 111-118.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Manthey L, van Veen T, Giltay EJ, et al. Correlates of benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA). Br J Clin Pharmacol, 2011, 71: 263-272.</mixed-citation><mixed-citation xml:lang="en">Manthey L, van Veen T, Giltay EJ, et al. Correlates of benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA). Br J Clin Pharmacol, 2011, 71: 263-272.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Menkes DB. Buspirone augmentation of sertraline. Br. J. Psychiatry, 1995, 166: 823-824.</mixed-citation><mixed-citation xml:lang="en">Menkes DB. Buspirone augmentation of sertraline. Br. J. Psychiatry, 1995, 166: 823-824.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull, 2005, 135: 785-795.</mixed-citation><mixed-citation xml:lang="en">Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull, 2005, 135: 785-795.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pakkanen Б, Kanto J, Kangas L, Mansikka М. Comparative study of the clinical effects of tofizopam, nitrazepam and placebo as oral premedication. Br J Anaesth, 1980, 52(10): 1009-12.</mixed-citation><mixed-citation xml:lang="en">Pakkanen Б, Kanto J, Kangas L, Mansikka М. Comparative study of the clinical effects of tofizopam, nitrazepam and placebo as oral premedication. Br J Anaesth, 1980, 52(10): 1009-12.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">PetTicz L. Pharmacologic effects of tofizopam (Grandaxin). Acta Pharm Hung, 1993, 63(2): 79-82.</mixed-citation><mixed-citation xml:lang="en">PetTicz L. Pharmacologic effects of tofizopam (Grandaxin). Acta Pharm Hung, 1993, 63(2): 79-82.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Saano V, Tacke U, Sopanen L, Airaksinen MM. Tofizopam enhances the action of diazepam against tremor and convulsions. Med Biol, 1983, 61(1): 49-53.</mixed-citation><mixed-citation xml:lang="en">Saano V, Tacke U, Sopanen L, Airaksinen MM. Tofizopam enhances the action of diazepam against tremor and convulsions. Med Biol, 1983, 61(1): 49-53.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sramek JJ, Hong WW, Hamid S, Nape B, Cutler NR. Meta-analysis of the safety and tolerability of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder. Drug Saf, 1997, 16: 118-132.</mixed-citation><mixed-citation xml:lang="en">Sramek JJ, Hong WW, Hamid S, Nape B, Cutler NR. Meta-analysis of the safety and tolerability of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder. Drug Saf, 1997, 16: 118-132.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
